STAT

‘How long do I have?’ A website on cancer survival rates, from the co-founder of GoodRx, seeks to provide clarity

A new online tool from the co-founder of GoodRx seeks to answer a simple but daunting question for cancer patients: "How long do I have?"

Talking about cancer is hard. Talking about your chances of surviving cancer is even harder.

Now one of the entrepreneurs behind the drug-pricing information site GoodRx wants to make conversations about cancer easier with a new site called CancerSurvivalRates.com. Launched this month, its mission is to make information about cancer prognoses more accessible to patients and families. The idea is to improve on what people can find on the internet or even sometimes in their doctors’ offices, co-founder and drug supply chain veteran Stephen Buck said.

Oncologists may be leery of their patients’ relying on the web

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks